Methods for the detection and treatment of classes of hepatocellular carcinoma responsive to immunotherapy
AssigneeIcahn School of Medicine at Mount Sinai
InventorsDaniela Sia, Josep Maria Llovet I Bayer, Augusto Villanueva-Rodriguez
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for detecting, diagnosing, prognosing, monitoring, and treating a patient with hepatocellular carcinoma. In particular, the invention provides diagnostic markers for the detection and treatment of patients who would benefit from immunotherapy, i.e., patient who would be most responsive to immunotherapy.
Claims23
-6. (canceled)
A method of treating a subject with hepatocellular carcinoma, comprising
- a. assaying gene expression levels of one or more genes in Table 3 in a sample from the subject with hepatocellular carcinoma to obtain a test expression profile;
- b. comparing the test expression profile of the genes with a reference expression profile, wherein the reference expression profile comprises a reference expression level of the same genes in a sample from a control;
- c. detecting the gene expression levels of one or more genes in the test expression profile are the same as compared to expression level of the same genes in the reference expression profile that is indicative of immunotherapy responsive phenotype;
- and
- d. treating the subject with immunotherapy.
(canceled)
A method of treating a subject with hepatocellular carcinoma, comprising
- a. assaying gene expression levels of one or more genes in Table 3 in a sample from the subject with hepatocellular carcinoma to obtain a first test expression profile;
- b. comparing the first test expression profile of the one or more genes in Table 3 with a first reference expression profile, wherein the first reference expression profile comprises a reference expression level of the same genes in a sample from a control;
- c. detecting the gene expression levels of one or more genes in the first test expression profile are the same as compared to expression level of the same genes in the first reference expression profile that is indicative of immunotherapy responsive phenotype and further detecting that the subject would be responsive to immunotherapy;
- d. assaying the gene expression levels of one or more genes in FIG. 12 in a sample from the subject with hepatocellular carcinoma to obtain a second test expression profile;
- e. comparing the second expression profile of the one or more gene pathways in FIG. 12 with a second reference expression profile, wherein the second expression profile comprises a reference expression level of the same genes in a sample from a control;
- f. detecting the gene expression levels of one or more genes in the first test expression profile are the same as compared to expression level of the same genes in the second reference expression profile that is indicative of the Exhausted Immune Response class;
- and
- g. treating the subject with a combination of immunotherapy and a second agent.
(canceled)
-35. (canceled)
A kit for the detection of a phenotype that is responsive to immunotherapy in a subject diagnosed with hepatocellular carcinoma, comprising probes for one or more of the genes listed in Table 3, reagents for isolating and purifying nucleic acids from biological tissue or bodily fluid, reagents for performing assays on the isolated and purified nucleic acid, instructions for use, and reference values or the means for obtaining reference values in a control sample for the included genes.
Dependencies are inferred from the claim text.